Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention

Table 1 Histone methyltransferase inhibitors reduce transformation of HBECs in conjunction with reprogramming of the transcription

Cell line	Treatment	Transformation^a	50–100%	> 100%	Total
Cell line	Treatment	(% Reduction)	50–100%	(Change in expression # genes)	Total
HBEC2T	DZNep	80 ± 2	1675	976	2651
	EPZ6438	70 ± 3	328	160	488
	UNC0642	0	85	23	108
	EPZ/UNC	70 ± 4	574	323	897
	Lovaza	30 ± 3	20	2	22
HBEC13T	DZNep	80 ± 3	838	332	1170
	EPZ6438	0	211	76	287
	UNC0642	0	80	25	153
	EPZ/UNC	48 ± 4	265	109	374
	Lovaza	28 ± 3	22	1	23

^aMean ± SD % reduction in transformation from triplicate soft agar assays compared to vehicle

ISSN: 1868-7083